This inventor holds 1 USPTO granted patent. Top assignee: Glaxo Group Limited. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: Clive A Halliday: Innovator in Medicinal Chemistry
Introduction
Clive A Halliday is a notable inventor based in Hertfordshire, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating anxiety. His work has led to the filing of a patent that showcases his innovative approach to pharmacology.
Latest Patents
Halliday holds a patent for a medicament that utilizes a specific compound for the treatment, relief, or prevention of anxiety effects. The patent, described in UK Published Patent Application No. 2157691A, focuses on the compound of formula (II) or its physiologically acceptable salt or hydrate. The preferred compound for this application is (±)-trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]-benzodioxino[2,3-c]-pyrrole, particularly in the form of its hydrochloride salt. This innovation represents a significant advancement in therapeutic options for individuals suffering from anxiety.
Career Highlights
Clive A Halliday is associated with Glaxo Group Limited, a prominent company in the pharmaceutical industry. His role at Glaxo has allowed him to collaborate with other experts in the field, enhancing the development of new medicinal products. His dedication to research and innovation has positioned him as a valuable asset in the realm of drug development.
Collaborations
One of Halliday's notable collaborators is Nigel Robert Oakley. Their partnership has contributed to the advancement of medicinal chemistry and the exploration of new therapeutic compounds.
Conclusion
Clive A Halliday's contributions to medicinal chemistry, particularly through his patent for anxiety treatment, highlight his innovative spirit and commitment to improving healthcare. His work continues to influence the pharmaceutical landscape, paving the way for future advancements in the field.